Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts ETON Hot Sheet
Join SI Premium – FREE
Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.43, $0.28 better than the analyst estimate of $0.15. Revenue for the quarter came in at $37.6 million versus the consensus estimate of $26.88 million.
GUIDANCE:
Eton Pharmaceuticals Inc. sees FY2026 revenue of $145 million, versus the consensus of $121 million.
For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Portillo's Inc. (PTLO) Tops Q3 EPS by 3c; Offers Guidance
- Parker-Hannifin (PH) Tops Q1 EPS by 69c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
